BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 24, 2008
 |  BioCentury  |  Regulation

End of life candidates

End of life candidates

Drug Company Indication First appraisal committee meeting
Erbitux cetuximab ImClone (NASDAQ:IMCL)/Bristol-Myers (NYSE:BMY)/Merck KGaA (Xetra:MRK) Metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN) 1/6/09
Sutent sunitinib Pfizer (NYSE:PFE) Gastrointestinal stromal...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >